Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HOUSE VERSION OF FDA COMMISSIONER BILL IS PREFERRED BY AGENCY

Executive Summary

HOUSE VERSION OF FDA COMMISSIONER BILL IS PREFERRED BY AGENCY over a version that passed the Senate Feb. 4. The agency prefers the less detailed language contained in Rep. Waxman's (D-Calif.) bill, which passed the House last spring. Sen. Gore's (D-Tenn.) bill contains a list of specified duties of the FDA Commissioner, which the FDA feels is unduly restrictive. HHS opposes the overall concept of Senate confirmation on the grounds that it is unnecessary. Under the Senate bill, the commissioner's authority includes "providing overall direction to the FDA and establishing and implementing general policies respecting the management and operation of programs and activities of the FDA." The legislation also makes the commissioner responsible for "research relating to foods, drugs, cosmetics, and devices" and for "engaging in educational and public information programs." The Senate bill further stipulates that the commissioner may "establish such technical and scientific review groups as are needed to carry out the functions of the Administration, including functions under the FD&C Act." Early in the Reagan Administration, several FDA advisory committees contained numerous vacancies due to delays as the Office of Management & Budget screened agency nominees to fill those slots. The legislation, which passed both the House and Senate in different forms at the close of the 99th Congress, is also intended to prevent situations where FDA's scientific decisions are overruled by OMB as overly burdensome for industry. Administration critics have said OMB has interfered with FDA decision-making with regard to such regulatory matters as Reye's Syndrome warning requirements for aspirin, color additive regulation, health claims for food, and warning labels for oral, liquid prescription drugs containing aspartame. On the Senate floor, Gore asserted that "the current arrangement has resulted in serious delays that have endangered the public health and cost industry millions of dollars." Under Gore's bill, FDA would be "more independent" but would remain within HHS, unlike the Consumer Product Safety Commission, which is not an agency of the department. The House bill, sponsored by Rep. Waxman (D-Calif.), simply requires Senate confirmation of commissioner appointees. A timetable for a House-Senate conference has not been set.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel